Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Study inclusion criteria

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Criteria Definition
Population Patients infected with hepatitis C virus (HCV) not co-infected with HIV.
Intervention Pegylated interferon alfa – 2a plus ribavirin (RBV)
Comparator Pegylated interferon alfa – 2b plus ribavirin
Outcome Sustained Virological Response (SVR)
Study type Randomized controlled trials